[
  {
    "id": 2549,
    "type": "Cover Page",
    "title": "Cover Page",
    "authors": [],
    "abstract": "",
    "abstractHtml": "",
    "previewText": "",
    "keywords": [],
    "doi": "",
    "received": "",
    "accepted": "",
    "published": "2023-01-01",
    "volume": 40,
    "issue": "6",
    "pages": "",
    "views": 0,
    "downloads": 0,
    "citations": 0,
    "featured": false,
    "imageCorner": false,
    "hasFullText": false,
    "sourceIssueId": "1287",
    "sourceArticleId": "2549",
    "sourceAbstractUrl": "",
    "sourceTextUrl": "",
    "sourcePdfUrl": "https://balkanmedicaljournal.org/pdf.php?&id=2549",
    "localPdfUrl": "js/data/pdfs/2549.pdf",
    "pdfUrl": "js/data/pdfs/2549.pdf"
  },
  {
    "id": 2545,
    "type": "Editorial",
    "title": "Beyond Tuberculosis: The Growing Threat of Nontuberculous Mycobacteria",
    "authors": [
      {
        "name": "Ethem Yıldız",
        "affiliation": "Department of Chest Diseases, Trakya University Faculty of Medicine, Edirne, Türkiye",
        "orcid": ""
      }
    ],
    "abstract": "",
    "abstractHtml": "",
    "previewText": "Nontuberculous mycobacteria (NTM) are mycobacterial pathogens other than Mycobacterium tuberculosis or Mycobacterium leprae.1 Even when this group of bacteria was named, they lagged behind the fame of tuberculosis, which is as old as human history. They have been labeled “atypical” simply because they are not mycobacterium tuberculosis. Similarly, their most",
    "keywords": [],
    "doi": "10.4274/balkanmedj.galenos.2023.2023-28092023",
    "received": "",
    "accepted": "",
    "published": "2023-01-01",
    "volume": 40,
    "issue": "6",
    "pages": "384-385",
    "views": 5519,
    "downloads": 3195,
    "citations": 0,
    "featured": false,
    "imageCorner": false,
    "hasFullText": true,
    "sourceIssueId": "1287",
    "sourceArticleId": "2545",
    "sourceAbstractUrl": "https://balkanmedicaljournal.org/abstract.php?id=2545",
    "sourceTextUrl": "https://balkanmedicaljournal.org/text.php?lang=en&id=2545",
    "sourcePdfUrl": "https://balkanmedicaljournal.org/pdf.php?&id=2545",
    "localPdfUrl": "js/data/pdfs/2545.pdf",
    "pdfUrl": "js/data/pdfs/2545.pdf"
  },
  {
    "id": 2543,
    "type": "Invited Review",
    "title": "Catheter Ablation Approaches for the Treatment of Arrhythmia Recurrence in Patients with a Durable Pulmonary Vein Isolation",
    "authors": [
      {
        "name": "Vinitha Nesapiragasan",
        "affiliation": "Clinics for Electrophysiology, Herz- und Diabeteszentrum Nordrhein-Westfalen, Ruhr-Universität Bochum, Bad Oeynhausen, Germany",
        "orcid": ""
      },
      {
        "name": "Mert İlker Hayıroğlu",
        "affiliation": "Clinic Cardiology, Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, İstanbul, Türkiye",
        "orcid": ""
      },
      {
        "name": "Vanessa Sciacca",
        "affiliation": "Clinics for Electrophysiology, Herz- und Diabeteszentrum Nordrhein-Westfalen, Ruhr-Universität Bochum, Bad Oeynhausen, Germany",
        "orcid": ""
      },
      {
        "name": "Philipp Sommer",
        "affiliation": "Clinics for Electrophysiology, Herz- und Diabeteszentrum Nordrhein-Westfalen, Ruhr-Universität Bochum, Bad Oeynhausen, Germany",
        "orcid": ""
      },
      {
        "name": "Christian Sohns",
        "affiliation": "Clinics for Electrophysiology, Herz- und Diabeteszentrum Nordrhein-Westfalen, Ruhr-Universität Bochum, Bad Oeynhausen, Germany",
        "orcid": ""
      },
      {
        "name": "Thomas Fink[[1]] <",
        "affiliation": "",
        "orcid": ""
      }
    ],
    "abstract": "Abstract Catheter ablation has emerged as an effective treatment for atrial arrhythmias, and pulmonary vein isolation (PVI) is the cornerstone of ablation strategies. Significant technological evolution and widespread increase in operator experience have facilitated the effectiveness of catheter ablation to achieve durable PVIs in single or multiple ablation procedures. Nevertheless, arrhythmia recurrence is a common problem even after establishing PVI. Data on catheter ablation in these patients are sparse and repeat ablation in this population is highly challenging. In this review we have summarized the available data as well as potential strategies of catheter ablation following the initial PVI.",
    "abstractHtml": "<div class=\"col-lg-12 col-md-12 col-sm-12 col-xs-12\">\n\t\t\t<h4>Abstract</h4>\r\n<p>Catheter ablation has emerged as an effective treatment for atrial arrhythmias, and pulmonary vein isolation (PVI) is the cornerstone of ablation strategies. Significant technological evolution and widespread increase in operator experience have facilitated the effectiveness of catheter ablation to achieve durable PVIs in single or multiple ablation procedures. Nevertheless, arrhythmia recurrence is a common problem even after establishing PVI. Data on catheter ablation in these patients are sparse and repeat ablation in this population is highly challenging. In this review we have summarized the available data as well as potential strategies of catheter ablation following the initial PVI.</p> \t\t\t\t\t\t        \t\t\t\t\t\n\t\t\t</div>",
    "previewText": "Abstract Catheter ablation has emerged as an effective treatment for atrial arrhythmias, and pulmonary vein isolation (PVI) is the cornerstone of ablation strategies. Significant technological evolution and widespread increase in operator experience have facilitated the effectiveness of catheter ablation to achieve durable PVIs in single or multiple ablation procedures. Nevertheless, arrhythmia recurrence is a common problem even after establishing PVI. Data on catheter ablation in these patients are sparse and repeat ablation in this population is highly challenging. In this review we have summarized the available data as well as potential strategies of catheter ablation following the initial PVI.",
    "keywords": [],
    "doi": "10.4274/balkanmedj.galenos.2023.2023-9-48",
    "received": "",
    "accepted": "",
    "published": "2023-01-01",
    "volume": 40,
    "issue": "6",
    "pages": "386-394",
    "views": 7062,
    "downloads": 4514,
    "citations": 0,
    "featured": false,
    "imageCorner": false,
    "hasFullText": true,
    "sourceIssueId": "1287",
    "sourceArticleId": "2543",
    "sourceAbstractUrl": "https://balkanmedicaljournal.org/abstract.php?id=2543",
    "sourceTextUrl": "https://balkanmedicaljournal.org/text.php?lang=en&id=2543",
    "sourcePdfUrl": "https://balkanmedicaljournal.org/pdf.php?&id=2543",
    "localPdfUrl": "js/data/pdfs/2543.pdf",
    "pdfUrl": "js/data/pdfs/2543.pdf"
  },
  {
    "id": 2534,
    "type": "Invited Review",
    "title": "Medical Education in the Era of Advancing Technology",
    "authors": [
      {
        "name": "Burcu Tokuç",
        "affiliation": "Department of Medical Education, Tekirdağ Namık Kemal University Faculty of Medicine, Tekirdağ, Türkiye",
        "orcid": ""
      },
      {
        "name": "Gamze Varol",
        "affiliation": "Department of Public Health, Tekirdağ Namık Kemal University Faculty of Medicine, Tekirdağ, Türkiye",
        "orcid": ""
      }
    ],
    "abstract": "Abstract Technology is developing rapidly and affecting the field of medicine in two main areas- medical education and health care. As a rapidly evolving field with the need and ability to constantly incorporate newer technologies, medical education must be able to prepare future doctors as per changing trends in practice patterns, the role of medicine in disease diagnosis and treatment, and innovations, and advances in medical science. In this article, we discuss the various digital learning tools introduced into medical education, as well as their advantages and disadvantages. We also try to understand how the shift to artificial intelligence may affect medical education and practice and how we can make technology efficient without losing the human dimension in doctor-patient relationships.",
    "abstractHtml": "<div class=\"col-lg-12 col-md-12 col-sm-12 col-xs-12\">\n\t\t\t<h4>Abstract</h4>\r\n<p>Technology is developing rapidly and affecting the field of medicine in two main areas- medical education and health care. As a rapidly evolving field with the need and ability to constantly incorporate newer technologies, medical education must be able to prepare future doctors as per changing trends in practice patterns, the role of medicine in disease diagnosis and treatment, and innovations, and advances in medical science. In this article, we discuss the various digital learning tools introduced into medical education, as well as their advantages and disadvantages. We also try to understand how the shift to artificial intelligence may affect medical education and practice and how we can make technology efficient without losing the human dimension in doctor-patient relationships.</p> \t\t\t\t\t\t        \t\t\t\t\t\n\t\t\t</div>",
    "previewText": "Abstract Technology is developing rapidly and affecting the field of medicine in two main areas- medical education and health care. As a rapidly evolving field with the need and ability to constantly incorporate newer technologies, medical education must be able to prepare future doctors as per changing trends in practice patterns, the role of medicine in disease diagnosis and treatment, and innovations, and advances in medical science. In this article, we discuss the various digital learning tools introduced into medical education, as well as their advantages and disadvantages. We also try to understand how the shift to artificial intelligence may affect medical education and practice and how we can make technology efficient without losing the human dimension in doctor-patient relationships.",
    "keywords": [],
    "doi": "10.4274/balkanmedj.galenos.2023.2023-7-79",
    "received": "",
    "accepted": "",
    "published": "2023-01-01",
    "volume": 40,
    "issue": "6",
    "pages": "395-399",
    "views": 6327,
    "downloads": 5425,
    "citations": 0,
    "featured": false,
    "imageCorner": false,
    "hasFullText": true,
    "sourceIssueId": "1287",
    "sourceArticleId": "2534",
    "sourceAbstractUrl": "https://balkanmedicaljournal.org/abstract.php?id=2534",
    "sourceTextUrl": "https://balkanmedicaljournal.org/text.php?lang=en&id=2534",
    "sourcePdfUrl": "https://balkanmedicaljournal.org/pdf.php?&id=2534",
    "localPdfUrl": "js/data/pdfs/2534.pdf",
    "pdfUrl": "js/data/pdfs/2534.pdf"
  },
  {
    "id": 2538,
    "type": "Meta-Analysis",
    "title": "Dasiglucagon for the Treatment of Insulin-induced Hypoglycemia in Patients with Type 1 Diabetes Mellitus: A Meta-analysis",
    "authors": [
      {
        "name": "Shampa Maji",
        "affiliation": "Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, India",
        "orcid": ""
      },
      {
        "name": "Rashmi Ranjan Mohanty",
        "affiliation": "Department of General Medicine, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, India",
        "orcid": ""
      },
      {
        "name": "Rituparna Maiti",
        "affiliation": "Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, India",
        "orcid": ""
      }
    ],
    "abstract": "Abstract Background: The use of conventional glucagon for managing insulin-induced hypoglycemia is obscured by its chemical instability and the need for reconstitution of the lyophilized powder, leading to delayed rescue. Dasiglucagon, a glucagon analog, may potentially overcome these shortcomings.Aims: To evaluate the efficacy and safety of dasiglucagon in insulin-induced hypoglycemia in patients with type 1 diabetes mellitus (T1DM).Study Design: Meta-analysis.Methods: PubMed/MEDLINE, Scopus, Embase, and Cochrane databases along with clinical trial registries were searched to include data from five randomized controlled trials conducted using dasiglucagon for the treatment of insulin-induced hypoglycemia in T1DM patients published until May 2023. We performed a risk of bias assessment to determine the quality of the included studies and a random-effects model analysis for determining the effect size. Subgroup analysis and meta-regression were done as applicable.Results: The time to recovery (in minutes) with dasiglucagon was earlier than placebo [mean difference (MD): -24.73; 95% confidence interval (CI): -30.94 to -18.52; p < 0.00001) or oral glucose (MD: -15.00; 95% CI: -20.33 to -9.67; p < 0.00001); however, the difference between dasiglucagon and glucagon was not statistically significant (MD: -0.76; 95% CI: -2.19 to 0.66; p = 0.29).Conclusion: Dasiglucagon is safer and more effective than placebo or oral glucose for insulin-induced hypoglycemia in T1DM patients; however, it is not superior to conventional glucagon.",
    "abstractHtml": "<div class=\"col-lg-12 col-md-12 col-sm-12 col-xs-12\">\n\t\t\t<h4>Abstract</h4>\r\n<p><strong>Background:</strong> The use of conventional glucagon for managing insulin-induced hypoglycemia is obscured by its chemical instability and the need for reconstitution of the lyophilized powder, leading to delayed rescue. Dasiglucagon, a glucagon analog, may potentially overcome these shortcomings.<br /><strong>Aims:</strong> To evaluate the efficacy and safety of dasiglucagon in insulin-induced hypoglycemia in patients with type 1 diabetes mellitus (T1DM).<br /><strong>Study Design:</strong> Meta-analysis.<br /><strong>Methods:</strong> PubMed/MEDLINE, Scopus, Embase, and Cochrane databases along with clinical trial registries were searched to include data from five randomized controlled trials conducted using dasiglucagon for the treatment of insulin-induced hypoglycemia in T1DM patients published until May 2023. We performed a risk of bias assessment to determine the quality of the included studies and a random-effects model analysis for determining the effect size. Subgroup analysis and meta-regression were done as applicable.<br /><strong>Results:</strong> The time to recovery (in minutes) with dasiglucagon was earlier than placebo [mean difference (MD): -24.73; 95% confidence interval (CI): -30.94 to -18.52; <em>p</em> &lt; 0.00001) or oral glucose (MD: -15.00; 95% CI: -20.33 to -9.67; <em>p</em> &lt; 0.00001); however, the difference between dasiglucagon and glucagon was not statistically significant (MD: -0.76; 95% CI: -2.19 to 0.66; <em>p </em>= 0.29).<br /><strong>Conclusion:</strong> Dasiglucagon is safer and more effective than placebo or oral glucose for insulin-induced hypoglycemia in T1DM patients; however, it is not superior to conventional glucagon.</p> \t\t\t\t\t\t        \t\t\t\t\t\n\t\t\t</div>",
    "previewText": "Abstract Background: The use of conventional glucagon for managing insulin-induced hypoglycemia is obscured by its chemical instability and the need for reconstitution of the lyophilized powder, leading to delayed rescue. Dasiglucagon, a glucagon analog, may potentially overcome these shortcomings.Aims: To evaluate the efficacy and safety of dasiglucagon in insulin-induced hypoglycemia in patients with type 1 diabetes mellitus (T1DM).Study Design: Meta-analysis.Methods: PubMed/MEDLINE, Scopus, Embase, and Cochrane databases along with clinical trial registries were searched to include data from five randomized controlled trials conducted using dasiglucagon for the treatment of insulin-induced hypoglycemia in T1DM patients published until May 2023. We performed a risk of bias assessment to determine the quality of the included studies and a random-effects model analysis for determining the effect size. Subgroup analysis and meta-regression were done as applicable.Results: The time to recovery (in minutes) with dasiglucagon was earlier than placebo [mean difference (MD): -24.73; 95% confidence interval (CI): -30.94 to -18.52; p < 0.00001) or oral glucose (MD: -15.00; 95% CI: -20.33 to -9.67; p < 0.00001); however, the difference between dasiglucagon and glucagon was not statistically significant (MD: -0.76; 95% CI: -2.19 to 0.66; p = 0.29).Conclusion: Dasiglucagon is safer and more effective than placebo or oral glucose for insulin-induced hypoglycemia in T1DM patients; however, it is not superior to conventional glucagon.",
    "keywords": [],
    "doi": "10.4274/balkanmedj.galenos.2023.2023-7-84",
    "received": "",
    "accepted": "",
    "published": "2023-01-01",
    "volume": 40,
    "issue": "6",
    "pages": "400-408",
    "views": 7000,
    "downloads": 3797,
    "citations": 0,
    "featured": false,
    "imageCorner": false,
    "hasFullText": true,
    "sourceIssueId": "1287",
    "sourceArticleId": "2538",
    "sourceAbstractUrl": "https://balkanmedicaljournal.org/abstract.php?id=2538",
    "sourceTextUrl": "https://balkanmedicaljournal.org/text.php?lang=en&id=2538",
    "sourcePdfUrl": "https://balkanmedicaljournal.org/pdf.php?&id=2538",
    "localPdfUrl": "js/data/pdfs/2538.pdf",
    "pdfUrl": "js/data/pdfs/2538.pdf"
  },
  {
    "id": 2521,
    "type": "Original Article",
    "title": "ELK4 Promotes Cell Cycle Progression and Stem Cell-like Characteristics in HPV-associated Cervical Cancer by Regulating the FBXO22/PTEN Axis",
    "authors": [
      {
        "name": "Fuxian Gao",
        "affiliation": "Department of Gynecology, Cangzhou People’s Hospital, Cangzhou, China",
        "orcid": ""
      },
      {
        "name": "Chunxiao Wang",
        "affiliation": "Department of Gynecology, Cangzhou People’s Hospital, Cangzhou, China",
        "orcid": ""
      },
      {
        "name": "Xue Bai",
        "affiliation": "Department of Gynecology, Cangzhou People’s Hospital, Cangzhou, China",
        "orcid": ""
      },
      {
        "name": "Jianghai Ji",
        "affiliation": "Department of Gynecology, Cangzhou People’s Hospital, Cangzhou, China",
        "orcid": ""
      },
      {
        "name": "Xinrui Huang",
        "affiliation": "Department of Gynecology, Cangzhou People’s Hospital, Cangzhou, China",
        "orcid": ""
      }
    ],
    "abstract": "Abstract Background: Cervical cancer (CC) is a prevalent gynecological carcinoma, and patients infected with human papillomavirus (HPV) have a higher morbidity rate.Aims: To explore the effects of ETS-like transcription factor 4 (ELK4) in patients with HPV+ CC.Study design: In vitro cell lines and human-sample study.Methods: The ELK4 levels in human tissue (65 HPV+ CC tissue and 25 HPV− normal cervical tissue) and cell lines (human cervical epithelial immortalized cell line H8 and CC cell lines HeLa [HPV18], CaSki [HPV16], and SiHa [HPV−]) were quantified using qRT-PCR and western blot assay. ELK4 knockdown transfection was effective and confirmed by western blotting. The MTT and EDU assays were used to evaluate cell viability and proliferation, respectively. Flow cytometry was used to detect the CC cell cycle stage. Stem cell markers, such as cluster of differentiation 133 (CD133), CD44, and aldehyde dehydrogenase 1, and the cervicospheres formed were measured. ChIP-qPCR and luciferase activity experiments were used to assess the bond between ELK4 and F-box protein 22 (FBXO22).Results: ELK4 was highly expressed in the HPV+ CC tissue. CC cells with ELK4 knockdown had lower viability and proliferation than the control cells. ELK4 knockdown blocked the progression of the cell cycle from G1 to S phase. ELK4 knockdown suppressed the stem cell-like characteristics of the HPV+ CC cells. ELK4 bonded with the FBXO22 promoter, inhibiting the levels of phosphatase and tensin homolog (PTEN).Conclusion: ELK4 facilitated cell cycle progression and stem cell-like characteristics by regulating the FBXO22/PTEN axis. Thus, ELK4 could be a potential therapeutic target to arrest the progress of HPV-associated CC.",
    "abstractHtml": "<div class=\"col-lg-12 col-md-12 col-sm-12 col-xs-12\">\n\t\t\t<h4>Abstract</h4>\r\n<p><strong>Background:</strong> Cervical cancer (CC) is a prevalent gynecological carcinoma, and patients infected with human papillomavirus (HPV) have a higher morbidity rate.<br /><strong>Aims: </strong>To explore the effects of ETS-like transcription factor 4 (ELK4) in patients with HPV<sup>+</sup> CC.<br /><strong>Study design:</strong> In vitro cell lines and human-sample study.<br /><strong>Methods:</strong> The ELK4 levels in human tissue (65 HPV<sup>+</sup> CC tissue and 25 HPV<sup>&minus;</sup> normal cervical tissue) and cell lines (human cervical epithelial immortalized cell line H8 and CC cell lines HeLa [HPV18], CaSki [HPV16], and SiHa [HPV<sup>&minus;</sup>]) were quantified using qRT-PCR and western blot assay. ELK4 knockdown transfection was effective and confirmed by western blotting. The MTT and EDU assays were used to evaluate cell viability and proliferation, respectively. Flow cytometry was used to detect the CC cell cycle stage. Stem cell markers, such as cluster of differentiation 133 (CD133), CD44, and aldehyde dehydrogenase 1, and the cervicospheres formed were measured. ChIP-qPCR and luciferase activity experiments were used to assess the bond between ELK4 and F-box protein 22 (FBXO22).<br /><strong>Results:</strong> ELK4 was highly expressed in the HPV<sup>+</sup> CC tissue. CC cells with ELK4 knockdown had lower viability and proliferation than the control cells. ELK4 knockdown blocked the progression of the cell cycle from G1 to S phase. ELK4 knockdown suppressed the stem cell-like characteristics of the HPV<sup>+</sup> CC cells. ELK4 bonded with the FBXO22 promoter, inhibiting the levels of phosphatase and tensin homolog (PTEN).<br /><strong>Conclusion:</strong> ELK4 facilitated cell cycle progression and stem cell-like characteristics by regulating the FBXO22/PTEN axis. Thus, ELK4 could be a potential therapeutic target to arrest the progress of HPV-associated CC.</p> \t\t\t\t\t\t        \t\t\t\t\t\n\t\t\t</div>",
    "previewText": "Abstract Background: Cervical cancer (CC) is a prevalent gynecological carcinoma, and patients infected with human papillomavirus (HPV) have a higher morbidity rate.Aims: To explore the effects of ETS-like transcription factor 4 (ELK4) in patients with HPV+ CC.Study design: In vitro cell lines and human-sample study.Methods: The ELK4 levels in human tissue (65 HPV+ CC tissue and 25 HPV− normal cervical tissue) and cell lines (human cervical epithelial immortalized cell line H8 and CC cell lines HeLa [HPV18], CaSki [HPV16], and SiHa [HPV−]) were quantified using qRT-PCR and western blot assay. ELK4 knockdown transfection was effective and confirmed by western blotting. The MTT and EDU assays were used to evaluate cell viability and proliferation, respectively. Flow cytometry was used to detect the CC cell cycle stage. Stem cell markers, such as cluster of differentiation 133 (CD133), CD44, and aldehyde dehydrogenase 1, and the cervicospheres formed were measured. ChIP-qPCR and luciferase activity experiments were used to assess the bond between ELK4 and F-box protein 22 (FBXO22).Results: ELK4 was highly expressed in the HPV+ CC tissue. CC cells with ELK4 knockdown had lower viability and proliferation than the control cells. ELK4 knockdown blocked the progression of the cell cycle from G1 to S phase. ELK4 knockdown suppressed the stem cell-like characteristics of the HPV+ CC cells. ELK4 bonded with the FBXO22 promoter, inhibiting the levels of phosphatase and tensin homolog (PTEN).Conclusion: ELK4 facilitated cell cycle progression and stem cell-like characteristics by regulating the FBXO22/PTEN axis. Thus, ELK4 could be a potential therapeutic target to arrest the progress of HPV-associated CC.",
    "keywords": [],
    "doi": "10.4274/balkanmedj.galenos.2023.2023-4-66",
    "received": "",
    "accepted": "",
    "published": "2023-01-01",
    "volume": 40,
    "issue": "6",
    "pages": "409-414",
    "views": 6723,
    "downloads": 4462,
    "citations": 0,
    "featured": false,
    "imageCorner": false,
    "hasFullText": true,
    "sourceIssueId": "1287",
    "sourceArticleId": "2521",
    "sourceAbstractUrl": "https://balkanmedicaljournal.org/abstract.php?id=2521",
    "sourceTextUrl": "https://balkanmedicaljournal.org/text.php?lang=en&id=2521",
    "sourcePdfUrl": "https://balkanmedicaljournal.org/pdf.php?&id=2521",
    "localPdfUrl": "js/data/pdfs/2521.pdf",
    "pdfUrl": "js/data/pdfs/2521.pdf"
  },
  {
    "id": 2535,
    "type": "Original Article",
    "title": "Does Maintaining a Targeted Abdominal Perfusion Pressure Reduce Renal Damage in Patients with Septic Shock?: A Randomized, Controlled, and Open-label Study",
    "authors": [
      {
        "name": "Hüseyin Özkarakaş",
        "affiliation": "Clinic of Intensive Care, University of Health Sciences Türkiye, İzmir Bozyaka Trainig and Research Hospital, İzmir, Türkiye",
        "orcid": ""
      },
      {
        "name": "Zeki Tuncel Tekgül",
        "affiliation": "Clinic of Intensive Care, University of Health Sciences Türkiye, İzmir Bozyaka Trainig and Research Hospital, İzmir, Türkiye",
        "orcid": ""
      },
      {
        "name": "Murat Arslan",
        "affiliation": "Clinic of Intensive Care, University of Health Sciences Türkiye, İzmir Bozyaka Trainig and Research Hospital, İzmir, Türkiye",
        "orcid": ""
      },
      {
        "name": "Mehmet Uğur Bilgin",
        "affiliation": "Clinic of Anesthesiology and Reanimation, Helios Klinikum Schleswig, Teaching Hospital for the University of Kiel, Kiel, Germany",
        "orcid": ""
      },
      {
        "name": "Hazal Ezgi Eker",
        "affiliation": "Clinic of Anesthesiology and Reanimation, İzmir Bayındır State Hospital, İzmir, Türkiye",
        "orcid": ""
      },
      {
        "name": "Onur Okur",
        "affiliation": "Clinic of Anesthesiology and Reanimation, University of Health Sciences Türkiye, Prof. Dr. Cemil Taşcıoğlu Training and Research Hospital, İstanbul, Türkiye",
        "orcid": ""
      },
      {
        "name": "Bülent Çalık",
        "affiliation": "Clinic of Intensive Care, University of Health Sciences Türkiye, İzmir Bozyaka Trainig and Research Hospital, İzmir, Türkiye",
        "orcid": ""
      }
    ],
    "abstract": "Abstract Background: Increased intra-abdominal pressure (IAP) in patients admitted to the intensive care unit leads to reduced abdominal perfusion pressure (APP), causing circulatory insufficiency and organ failure.Aims: To investigate the effect of maintaining a targeted APP on renal injury and the effect of increased IAP on the mortality rate in patients with septic shock.Study Design: Randomized, controlled, open-label study.Methods: A total of 72 patients were randomly divided into two groups (MAP65 or APP60). The MAP target for patients in the MAP65 group (n = 36) was 65 mmHg according to the Surviving Sepsis Guidelines. In the APP60 group (n = 36), the target APP was set to > 60 mmHg. The glomerular filtration rate (GFR), inotrope consumption, and IAP were recorded daily. The need for renal replacement therapy, decrease in GFR, and 30- and 90-day mortality rates were compared between the two groups.Results: In both the groups, the IAP was statistically similar (p = 0.458). The decreased in GFR was similar in both groups during the first 2 days. From day 3, there was a more statistically significant rapid decline in GFR in the MAP65 group than in the APP60 group. The GFR p-values on the 3rd, 4th, and 5th days were 0.040, 0.043, and 0.032, respectively. Eight patients (22.2%) in the MAP65 group and three patients (8.3%) in the APP group required renal replacement therapy (p = 0.101). The 30-day mortality rates in the MAP65 and APP60 groups were 61.1%, and 47.7%, respectively (p = 0.237). The 90-day mortality rates in the MAP65 and APP60 groups were 66.7% and 66.7%, respectively (p = 1).Conclusion: Setting an APP target limited the reduction in GFR. The mortality rates were similar in the two groups and there was no difference in the rate of end-stage renal failure between the groups.",
    "abstractHtml": "<div class=\"col-lg-12 col-md-12 col-sm-12 col-xs-12\">\n\t\t\t<h4>Abstract</h4>\r\n<p><strong>Background:</strong> Increased intra-abdominal pressure (IAP) in patients admitted to the intensive care unit leads to reduced abdominal perfusion pressure (APP), causing circulatory insufficiency and organ failure.<br /><strong>Aims:</strong> To investigate the effect of maintaining a targeted APP on renal injury and the effect of increased IAP on the mortality rate in patients with septic shock.<br /><strong>Study Design:</strong> Randomized, controlled, open-label study.<br /><strong>Methods:</strong> A total of 72 patients were randomly divided into two groups (MAP65 or APP60). The MAP target for patients in the MAP65 group (n = 36) was 65 mmHg according to the Surviving Sepsis Guidelines. In the APP60 group (n = 36), the target APP was set to &gt; 60 mmHg. The glomerular filtration rate (GFR), inotrope consumption, and IAP were recorded daily. The need for renal replacement therapy, decrease in GFR, and 30- and 90-day mortality rates were compared between the two groups.<br /><strong>Results:</strong> In both the groups, the IAP was statistically similar (<em>p</em> = 0.458). The decreased in GFR was similar in both groups during the first 2 days. From day 3, there was a more statistically significant rapid decline in GFR in the MAP65 group than in the APP60 group. The GFR p-values on the 3<sup>rd</sup>, 4<sup>th</sup>, and 5<sup>th</sup> days were 0.040, 0.043, and 0.032, respectively. Eight patients (22.2%) in the MAP65 group and three patients (8.3%) in the APP group required renal replacement therapy (<em>p</em> = 0.101). The 30-day mortality rates in the MAP65 and APP60 groups were 61.1%, and 47.7%, respectively (<em>p</em> = 0.237). The 90-day mortality rates in the MAP65 and APP60 groups were 66.7% and 66.7%, respectively (<em>p</em> = 1).<br /><strong>Conclusion:</strong> Setting an APP target limited the reduction in GFR. The mortality rates were similar in the two groups and there was no difference in the rate of end-stage renal failure between the groups.</p> \t\t\t\t\t\t        \t\t\t\t\t\n\t\t\t</div>",
    "previewText": "Abstract Background: Increased intra-abdominal pressure (IAP) in patients admitted to the intensive care unit leads to reduced abdominal perfusion pressure (APP), causing circulatory insufficiency and organ failure.Aims: To investigate the effect of maintaining a targeted APP on renal injury and the effect of increased IAP on the mortality rate in patients with septic shock.Study Design: Randomized, controlled, open-label study.Methods: A total of 72 patients were randomly divided into two groups (MAP65 or APP60). The MAP target for patients in the MAP65 group (n = 36) was 65 mmHg according to the Surviving Sepsis Guidelines. In the APP60 group (n = 36), the target APP was set to > 60 mmHg. The glomerular filtration rate (GFR), inotrope consumption, and IAP were recorded daily. The need for renal replacement therapy, decrease in GFR, and 30- and 90-day mortality rates were compared between the two groups.Results: In both the groups, the IAP was statistically similar (p = 0.458). The decreased in GFR was similar in both groups during the first 2 days. From day 3, there was a more statistically significant rapid decline in GFR in the MAP65 group than in the APP60 group. The GFR p-values on the 3rd, 4th, and 5th days were 0.040, 0.043, and 0.032, respectively. Eight patients (22.2%) in the MAP65 group and three patients (8.3%) in the APP group required renal replacement therapy (p = 0.101). The 30-day mortality rates in the MAP65 and APP60 groups were 61.1%, and 47.7%, respectively (p = 0.237). The 90-day mortality rates in the MAP65 and APP60 groups were 66.7% and 66.7%, respectively (p = 1).Conclusion: Setting an APP target limited the reduction in GFR. The mortality rates were similar in the two groups and there was no difference in the rate of end-stage renal failure between the groups.",
    "keywords": [],
    "doi": "10.4274/balkanmedj.galenos.2023.2023-5-9",
    "received": "",
    "accepted": "",
    "published": "2023-01-01",
    "volume": 40,
    "issue": "6",
    "pages": "415-421",
    "views": 5553,
    "downloads": 3562,
    "citations": 0,
    "featured": false,
    "imageCorner": false,
    "hasFullText": true,
    "sourceIssueId": "1287",
    "sourceArticleId": "2535",
    "sourceAbstractUrl": "https://balkanmedicaljournal.org/abstract.php?id=2535",
    "sourceTextUrl": "https://balkanmedicaljournal.org/text.php?lang=en&id=2535",
    "sourcePdfUrl": "https://balkanmedicaljournal.org/pdf.php?&id=2535",
    "localPdfUrl": "js/data/pdfs/2535.pdf",
    "pdfUrl": "js/data/pdfs/2535.pdf"
  },
  {
    "id": 2542,
    "type": "Original Article",
    "title": "Administration of Akebia Saponin D Improved Blood Lipid Levels and Pregnancy Outcomes in Mice with Gestational Diabetes Mellitus",
    "authors": [
      {
        "name": "Wei Chen",
        "affiliation": "Department of Obstetrical, The People’s Hospital of Danyang, Affiliated Danyang Hospital of Nantong University, Nantong, China",
        "orcid": ""
      },
      {
        "name": "Juan Shi",
        "affiliation": "Department of Obstetrical, The People’s Hospital of Danyang, Affiliated Danyang Hospital of Nantong University, Nantong, China",
        "orcid": ""
      },
      {
        "name": "Wei Zhang",
        "affiliation": "Department of Obstetrical, The People’s Hospital of Danyang, Affiliated Danyang Hospital of Nantong University, Nantong, China",
        "orcid": ""
      }
    ],
    "abstract": "Abstract Background: Gestational diabetes mellitus (GDM) is a prevalent and severe metabolic disease in pregnant women that is characterized by a high incidence. Placental oxidative stress and inflammation are recognized as the primary contributors to GDM pathogenesis. The repressive effect of akebia saponin D (ASD) on oxidative stress and inflammation has been demonstrated in various diseases.Aims: To investigate the impact of ASD on GDM.Study Design: Animal experimental study.Methods: GDM mice were intraperitoneally treated with ASD. The effect of ASD on GDM symptoms, blood lipid levels, pancreatic tissue damage, gestational outcomes, oxidative stress, and inflammation was assessed via intraperitoneal glucose and insulin tolerance tests, serum glucose and insulin level determination, lipid biochemistry analysis, pathological staining, oxidative stress evaluation, western blot analysis, and enzyme-linked immunosorbent assay.Results: ASD reduced the GDM-induced increase in body weight and blood glucose levels while restoring the decreased insulin levels associated with GDM. In addition, ASD improved the serum lipid parameters, pancreatic tissue damage, and gestational outcomes in GDM mice. Furthermore, ASD reversed the decreased levels of superoxide dismutase and glutathione while reducing the elevated concentrations of malondialdehyde and myeloperoxidase in GDM mice. In addition, ASD rescued the relative protein expression of nuclear factor-E2-related factor 2 and heme oxygenase-1 in the placenta of GDM mice. Additionally, ASD counteracted the increase in tumor necrosis factor-α, interleukin (IL)-6, and IL-1β levels in the sera and placenta of GDM mice.Conclusion: ASD suppressed oxidative stress and inflammation to effectively relieve symptoms and gestational outcomes of the GDM mice.",
    "abstractHtml": "<div class=\"col-lg-12 col-md-12 col-sm-12 col-xs-12\">\n\t\t\t<h4>Abstract</h4>\r\n<p><strong>Background:</strong> Gestational diabetes mellitus (GDM) is a prevalent and severe metabolic disease in pregnant women that is characterized by a high incidence. Placental oxidative stress and inflammation are recognized as the primary contributors to GDM pathogenesis. The repressive effect of akebia saponin D (ASD) on oxidative stress and inflammation has been demonstrated in various diseases.<br /><strong>Aims:</strong> To investigate the impact of ASD on GDM.<br /><strong>Study Design:</strong> Animal experimental study.<br /><strong>Methods:</strong> GDM mice were intraperitoneally treated with ASD. The effect of ASD on GDM symptoms, blood lipid levels, pancreatic tissue damage, gestational outcomes, oxidative stress, and inflammation was assessed via intraperitoneal glucose and insulin tolerance tests, serum glucose and insulin level determination, lipid biochemistry analysis, pathological staining, oxidative stress evaluation, western blot analysis, and enzyme-linked immunosorbent assay.<br /><strong>Results:</strong> ASD reduced the GDM-induced increase in body weight and blood glucose levels while restoring the decreased insulin levels associated with GDM. In addition, ASD improved the serum lipid parameters, pancreatic tissue damage, and gestational outcomes in GDM mice. Furthermore, ASD reversed the decreased levels of superoxide dismutase and glutathione while reducing the elevated concentrations of malondialdehyde and myeloperoxidase in GDM mice. In addition, ASD rescued the relative protein expression of nuclear factor-E2-related factor 2 and heme oxygenase-1 in the placenta of GDM mice. Additionally, ASD counteracted the increase in tumor necrosis factor-&alpha;, interleukin (IL)-6, and IL-1&beta; levels in the sera and placenta of GDM mice.<br /><strong>Conclusion:</strong> ASD suppressed oxidative stress and inflammation to effectively relieve symptoms and gestational outcomes of the GDM mice.</p> \t\t\t\t\t\t        \t\t\t\t\t\n\t\t\t</div>",
    "previewText": "Abstract Background: Gestational diabetes mellitus (GDM) is a prevalent and severe metabolic disease in pregnant women that is characterized by a high incidence. Placental oxidative stress and inflammation are recognized as the primary contributors to GDM pathogenesis. The repressive effect of akebia saponin D (ASD) on oxidative stress and inflammation has been demonstrated in various diseases.Aims: To investigate the impact of ASD on GDM.Study Design: Animal experimental study.Methods: GDM mice were intraperitoneally treated with ASD. The effect of ASD on GDM symptoms, blood lipid levels, pancreatic tissue damage, gestational outcomes, oxidative stress, and inflammation was assessed via intraperitoneal glucose and insulin tolerance tests, serum glucose and insulin level determination, lipid biochemistry analysis, pathological staining, oxidative stress evaluation, western blot analysis, and enzyme-linked immunosorbent assay.Results: ASD reduced the GDM-induced increase in body weight and blood glucose levels while restoring the decreased insulin levels associated with GDM. In addition, ASD improved the serum lipid parameters, pancreatic tissue damage, and gestational outcomes in GDM mice. Furthermore, ASD reversed the decreased levels of superoxide dismutase and glutathione while reducing the elevated concentrations of malondialdehyde and myeloperoxidase in GDM mice. In addition, ASD rescued the relative protein expression of nuclear factor-E2-related factor 2 and heme oxygenase-1 in the placenta of GDM mice. Additionally, ASD counteracted the increase in tumor necrosis factor-α, interleukin (IL)-6, and IL-1β levels in the sera and placenta of GDM mice.Conclusion: ASD suppressed oxidative stress and inflammation to effectively relieve symptoms and gestational outcomes of the GDM mice.",
    "keywords": [],
    "doi": "10.4274/balkanmedj.galenos.2023.2023-6-82",
    "received": "",
    "accepted": "",
    "published": "2023-01-01",
    "volume": 40,
    "issue": "6",
    "pages": "422-429",
    "views": 6364,
    "downloads": 4151,
    "citations": 0,
    "featured": false,
    "imageCorner": false,
    "hasFullText": true,
    "sourceIssueId": "1287",
    "sourceArticleId": "2542",
    "sourceAbstractUrl": "https://balkanmedicaljournal.org/abstract.php?id=2542",
    "sourceTextUrl": "https://balkanmedicaljournal.org/text.php?lang=en&id=2542",
    "sourcePdfUrl": "https://balkanmedicaljournal.org/pdf.php?&id=2542",
    "localPdfUrl": "js/data/pdfs/2542.pdf",
    "pdfUrl": "js/data/pdfs/2542.pdf"
  },
  {
    "id": 2541,
    "type": "Original Article",
    "title": "Role of Albumin-corrected Anion Gap and Lactate Clearance in Predicting Mortality in Pediatric Intensive Care Patients",
    "authors": [
      {
        "name": "Büşra Gündoğan Uzunay",
        "affiliation": "Department of Pediatrics, Akdeniz University Faculty of Medicine, Antalya, Türkiye",
        "orcid": ""
      },
      {
        "name": "Alper Köker",
        "affiliation": "Department of Pediatrics Intensive Care, Akdeniz University Faculty of Medicine, Antalya, Türkiye",
        "orcid": ""
      },
      {
        "name": "Nazan Ülgen Tekerek",
        "affiliation": "Department of Pediatrics Intensive Care, Akdeniz University Faculty of Medicine, Antalya, Türkiye",
        "orcid": ""
      },
      {
        "name": "Levent Dönmez",
        "affiliation": "Department of Public Health, Akdeniz University Faculty of Medicine, Antalya, Türkiye",
        "orcid": ""
      },
      {
        "name": "Oğuz Dursun",
        "affiliation": "Department of Pediatrics Intensive Care, Akdeniz University Faculty of Medicine, Antalya, Türkiye",
        "orcid": ""
      }
    ],
    "abstract": "Abstract Background: Identifying mortality risk in critically ill children is central to diagnostic and treatment practices. For this purpose, scoring systems, such as the Pediatric Index of Mortality 3 (PIM 3), have been proposed; however, the role of biochemical markers, such as albumin-corrected anion gap (cAG) and lactate clearance (LC), in predicting mortality in pediatric intensive care unit (PICU) patients is yet to be explored.Aims: To evaluate the predictive value of the cAG and LC for mortality in pediatric patients admitted to a PICU.Study Design: Retrospective single-center cohort study.Methods: Clinical and laboratory data from the time of PICU admission were collected, and patients were classified into based on their 0- and 6-hour of admission lactate levels into an LC(+) group (patients with normal or decreasing lactate levels) or an LC(−) group (increasing lactate levels). LC and cAG levels were compared using the Mann-Whitney U test and Student’s t-test, respectively. Additionally, multiple logistic regression analysis was performed to evaluate the effect of LC and cAG on mortality.Results: We included 825 patients in the study; the mortality rate was 8.6%. The absence of LC [adjusted odds ratio (AOR) =4.735; 95% confidence interval (CI): 2.163-10.367; p < 0.001], cAG (AOR =1.064; 95% CI: 1.010-1.122; p = 0.019) and PIM 3 (AOR = 1.871; 95% CI: 1.553-2.254; p < 0.001) were independent risk factors for mortality. Using the receiver operating characteristic curve analysis of PIM 3 as a predictor of mortality, area under the curve values of 0.832 (95% CI: 0.805-0.857; p < 0.001) for the original score and 0.858 for a revised PIM 3 score (based on the β coefficients obtained for cAG and LC; 95% CI 0.832-0.881; p < 0.001) were obtained, which was significantly different (p = 0.027).Conclusion: A cAG value > 18 at the time of PICU admission high lactate levels which do not decrease within 6 hours of hospitalization are associated with an increased risk of mortality. The revised PIM 3 score, which includes cAG and LC, is a better predictor of mortality than the classical PIM 3 score.",
    "abstractHtml": "<div class=\"col-lg-12 col-md-12 col-sm-12 col-xs-12\">\n\t\t\t<h4>Abstract</h4>\r\n<p><strong>Background: </strong>Identifying mortality risk in critically ill children is central to diagnostic and treatment practices. For this purpose, scoring systems, such as the Pediatric Index of Mortality 3 (PIM 3), have been proposed; however, the role of biochemical markers, such as albumin-corrected anion gap (cAG) and lactate clearance (LC), in predicting mortality in pediatric intensive care unit (PICU) patients is yet to be explored.<br /><strong>Aims: </strong>To evaluate the predictive value of the cAG and LC for mortality in pediatric patients admitted to a PICU.<br /><strong>Study Design:</strong> Retrospective single-center cohort study.<br /><strong>Methods</strong>: Clinical and laboratory data from the time of PICU admission were collected, and patients were classified into based on their 0- and 6-hour of admission lactate levels into an LC(+) group (patients with normal or decreasing lactate levels) or an LC(&minus;) group (increasing lactate levels). LC and cAG levels were compared using the Mann-Whitney U test and Student&rsquo;s t-test, respectively. Additionally, multiple logistic regression analysis was performed to evaluate the effect of LC and cAG on mortality.<br /><strong>Results:</strong> We included 825 patients in the study; the mortality rate was 8.6%. The absence of LC [adjusted odds ratio (AOR) =4.735; 95% confidence interval (CI): 2.163-10.367; <em>p</em> &lt; 0.001], cAG (AOR =1.064; 95% CI: 1.010-1.122; <em>p</em> = 0.019) and PIM 3 (AOR = 1.871; 95% CI: 1.553-2.254; <em>p </em>&lt; 0.001) were independent risk factors for mortality. Using the receiver operating characteristic curve analysis of PIM 3 as a predictor of mortality, area under the curve values of 0.832 (95% CI: 0.805-0.857; <em>p</em> &lt; 0.001) for the original score and 0.858 for a revised PIM 3 score (based on the &beta; coefficients obtained for cAG and LC; 95% CI 0.832-0.881; <em>p</em> &lt; 0.001) were obtained, which was significantly different (<em>p</em> = 0.027).<br /><strong>Conclusion:</strong> A cAG value &gt; 18 at the time of PICU admission high lactate levels which do not decrease within 6 hours of hospitalization are associated with an increased risk of mortality. The revised PIM 3 score, which includes cAG and LC, is a better predictor of mortality than the classical PIM 3 score.</p> \t\t\t\t\t\t        \t\t\t\t\t\n\t\t\t</div>",
    "previewText": "Abstract Background: Identifying mortality risk in critically ill children is central to diagnostic and treatment practices. For this purpose, scoring systems, such as the Pediatric Index of Mortality 3 (PIM 3), have been proposed; however, the role of biochemical markers, such as albumin-corrected anion gap (cAG) and lactate clearance (LC), in predicting mortality in pediatric intensive care unit (PICU) patients is yet to be explored.Aims: To evaluate the predictive value of the cAG and LC for mortality in pediatric patients admitted to a PICU.Study Design: Retrospective single-center cohort study.Methods: Clinical and laboratory data from the time of PICU admission were collected, and patients were classified into based on their 0- and 6-hour of admission lactate levels into an LC(+) group (patients with normal or decreasing lactate levels) or an LC(−) group (increasing lactate levels). LC and cAG levels were compared using the Mann-Whitney U test and Student’s t-test, respectively. Additionally, multiple logistic regression analysis was performed to evaluate the effect of LC and cAG on mortality.Results: We included 825 patients in the study; the mortality rate was 8.6%. The absence of LC [adjusted odds ratio (AOR) =4.735; 95% confidence interval (CI): 2.163-10.367; p < 0.001], cAG (AOR =1.064; 95% CI: 1.010-1.122; p = 0.019) and PIM 3 (AOR = 1.871; 95% CI: 1.553-2.254; p < 0.001) were independent risk factors for mortality. Using the receiver operating characteristic curve analysis of PIM 3 as a predictor of mortality, area under the curve values of 0.832 (95% CI: 0.805-0.857; p < 0.001) for the original score and 0.858 for a revised PIM 3 score (based on the β coefficients obtained for cAG and LC; 95% CI 0.832-0.881; p < 0.001) were obtained, which was significantly different (p = 0.027).Conclusion: A cAG value > 18 at the time of PICU admission high lactate levels which do not decrease within 6 hours of hospitalization are associated with an increased risk of mortality. The revised PIM 3 score, which includes cAG and LC, is a better predictor of mortality than the classical PIM 3 score.",
    "keywords": [],
    "doi": "10.4274/balkanmedj.galenos.2023.2023-7-87",
    "received": "",
    "accepted": "",
    "published": "2023-01-01",
    "volume": 40,
    "issue": "6",
    "pages": "430-434",
    "views": 5807,
    "downloads": 3545,
    "citations": 0,
    "featured": false,
    "imageCorner": false,
    "hasFullText": true,
    "sourceIssueId": "1287",
    "sourceArticleId": "2541",
    "sourceAbstractUrl": "https://balkanmedicaljournal.org/abstract.php?id=2541",
    "sourceTextUrl": "https://balkanmedicaljournal.org/text.php?lang=en&id=2541",
    "sourcePdfUrl": "https://balkanmedicaljournal.org/pdf.php?&id=2541",
    "localPdfUrl": "js/data/pdfs/2541.pdf",
    "pdfUrl": "js/data/pdfs/2541.pdf"
  },
  {
    "id": 2546,
    "type": "Original Article",
    "title": "The Impact of CoronaVac Vaccination on 28-day Mortality Rate of Critically Ill Patients with COVID-19 in Türkiye",
    "authors": [
      {
        "name": "Fethi Gül",
        "affiliation": "Division of Critical Care Medicine, Department of Anesthesiology and Reanimation, Marmara University Faculty of Medicine, İstanbul, Türkiye",
        "orcid": ""
      },
      {
        "name": "Umut Sabri Kasapoğlu",
        "affiliation": "Clinic of Critical Care Medicine, Malatya Training and Research Hospital, Malatya, Türkiye",
        "orcid": ""
      },
      {
        "name": "Mehmet Süleyman Sabaz",
        "affiliation": "Clinic of Critical Care Medicine, Marmara University Pendik Training and Research Hospital, İstanbul, Türkiye",
        "orcid": ""
      },
      {
        "name": "Pınar Ay",
        "affiliation": "Department of Public Health, Marmara University Faculty of Medicine, İstanbul, Türkiye",
        "orcid": ""
      },
      {
        "name": "Burçin Doruk Oktay",
        "affiliation": "Division of Critical Care Medicine, Department of Anesthesiology and Reanimation, Marmara University Faculty of Medicine, İstanbul, Türkiye",
        "orcid": ""
      },
      {
        "name": "Gülbahar Çalışkan",
        "affiliation": "Department of Anesthesiology and Reanimation, University of Health Sciences Türkiye, Bursa Faculty of Medicine, Bursa, Türkiye",
        "orcid": ""
      },
      {
        "name": "Nalan Demir",
        "affiliation": "Division of Critical Care Medicine, Clinic of Chest Diseases, University of Health Sciences Türkiye, Ankara City Hospital, Ankara, Türkiye",
        "orcid": ""
      },
      {
        "name": "İsmet Sayan",
        "affiliation": "Clinic of Critical Care Medicine, Sancaktepe Training and Research Hospital, İstanbul, Türkiye",
        "orcid": ""
      },
      {
        "name": "Feyyaz Kabadayı",
        "affiliation": "Clinic of Critical Care Medicine, Sancaktepe Training and Research Hospital, İstanbul, Türkiye",
        "orcid": ""
      },
      {
        "name": "Gülsüm Altuntaş",
        "affiliation": "Clinic of Critical Care Medicine, Elazığ City Hospital, Elazığ, Türkiye",
        "orcid": ""
      },
      {
        "name": "Ayça Gümüş",
        "affiliation": "Clinic of Critical Care Medicine, Antalya Kepez State Hospital, Antalya, Türkiye",
        "orcid": ""
      },
      {
        "name": "Hülya Kırca",
        "affiliation": "Clinic of Critical Care Medicine, Antalya Kepez State Hospital, Antalya, Türkiye",
        "orcid": ""
      },
      {
        "name": "Deniz Şanlı",
        "affiliation": "Clinic of Critical Care Medicine, Batman Training and Research Hospital, Batman, Türkiye",
        "orcid": ""
      },
      {
        "name": "Fatma Acil",
        "affiliation": "Clinic of Anesthesiology and Reanimation, University of Health Sciences Türkiye, Diyarbakır Gazi Yaşargil Training and Research Hospital, Diyabakır, Türkiye",
        "orcid": ""
      },
      {
        "name": "Andaç Dedeoğlu",
        "affiliation": "Clinic of Anesthesiology and Reanimation, University of Health Sciences Türkiye, Diyarbakır Gazi Yaşargil Training and Research Hospital, Diyabakır, Türkiye",
        "orcid": ""
      },
      {
        "name": "Sedef Gülçin Ural",
        "affiliation": "Clinic Critical Care Medicine, University of Health Sciences Türkiye, Erzurum City Hospital, Erzurum, Türkiye",
        "orcid": ""
      },
      {
        "name": "İrem Akın Şen",
        "affiliation": "Clinic Critical Care Medicine, University of Health Sciences Türkiye, Erzurum City Hospital, Erzurum, Türkiye",
        "orcid": ""
      },
      {
        "name": "Eda Macit Aydın",
        "affiliation": "Division of Critical Care Medicine, Clinic of Anesthesiology and Reanimation, University of Health Sciences Türkiye, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Türkiye",
        "orcid": ""
      },
      {
        "name": "Hakan Dayanır",
        "affiliation": "Division of Critical Care Medicine, Clinic of Anesthesiology and Reanimation, University of Health Sciences Türkiye, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Türkiye",
        "orcid": ""
      },
      {
        "name": "Birgül Yelken",
        "affiliation": "Division of Critical Care Medicine, Department of Anesthesiology and Reanimation, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Türkiye",
        "orcid": ""
      },
      {
        "name": "İlkay Ceylan",
        "affiliation": "Clinic of Critical Care Medicine, University of Health Sciences Türkiye, Bursa High Specialization Training and Research Hospital, Bursa, Türkiye",
        "orcid": ""
      },
      {
        "name": "Osman Özcan Aydın",
        "affiliation": "Division of Critical Care Medicine, Department of Anesthesiology and Reanimation, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Türkiye",
        "orcid": ""
      },
      {
        "name": "Güneş Eskidemir",
        "affiliation": "Clinic of Critical Care Medicine, Gaziosmanpaşa Training and Research Hospital, İstanbul, Türkiye",
        "orcid": ""
      },
      {
        "name": "Ahmet Aytekin",
        "affiliation": "Clinic of Anesthesiology and Reanimation, Göztepe Prof. Dr. Süleyman Yalçın City Hospital, İstanbul, Türkiye",
        "orcid": ""
      },
      {
        "name": "Melike Cengiz",
        "affiliation": "Division of Critical Care Medicine, Department of Anesthesiology and Reanimation, Akdeniz University Faculty of Medicine, Antalya, Türkiye",
        "orcid": ""
      },
      {
        "name": "Ülkü Arslan",
        "affiliation": "Division of Critical Care Medicine, Department of Anesthesiology and Reanimation, Akdeniz University Faculty of Medicine, Antalya, Türkiye",
        "orcid": ""
      },
      {
        "name": "Devrim Akdağ",
        "affiliation": "Clinic of Critical Care Medicine, University of Health Sciences Türkiye, Adana City Hospital, Adana, Türkiye",
        "orcid": ""
      },
      {
        "name": "Gülçin Hilal Alay",
        "affiliation": "Department of Anesthesiology and Reanimation, University of Health Sciences Türkiye, İstanbul Başakşehir Çam and Sakura City Hospital, İstanbul, Türkiye",
        "orcid": ""
      },
      {
        "name": "Esra Tekin",
        "affiliation": "Clinic of Critical Care Medicine, Denizli State Hospital, Denizli, Türkiye",
        "orcid": ""
      },
      {
        "name": "Volkan Yarar",
        "affiliation": "Clinic of Critical Care Medicine, Balıkesir Atatürk City Hospital, Balıkesir, Türkiye",
        "orcid": ""
      },
      {
        "name": "Kemal Tolga Saracoğlu",
        "affiliation": "Clinic of Anesthesiology and Reanimation, University of Health Sciences Türkiye, Kartal Lütfi Kırdar Training and Research Hospital, İstanbul, Türkiye",
        "orcid": ""
      },
      {
        "name": "Funda Gök",
        "affiliation": "Division of Critical Care Medicine, Department of Anesthesiology and Reanimation, Necmettin Erbakan University Faculty of Medicine, Konya, Türkiye",
        "orcid": ""
      },
      {
        "name": "Volkan Alparslan",
        "affiliation": "Clinic of Critical Care Medicine, Hatay Training and Research Hospital, Hatay, Türkiye",
        "orcid": ""
      },
      {
        "name": "Verda Tuna",
        "affiliation": "Clinic of Critical Care Medicine, Adıyaman Training and Research Hospital, Adıyaman, Türkiye",
        "orcid": ""
      },
      {
        "name": "Murside Yıldız",
        "affiliation": "Clinic of Critical Care Medicine, Ağrı Training and Research Hospital, Ağrı, Türkiye",
        "orcid": ""
      },
      {
        "name": "Nimet Şenoğlu",
        "affiliation": "Division of Critical Care Medicine, Clinic of Anesthesiology and Reanimation, University of Health Sciences Türkiye, Tepecik Training and Research Hospital, İzmir, Türkiye",
        "orcid": ""
      },
      {
        "name": "Cenk Kıraklı",
        "affiliation": "Department of Critical Care Medicine, University of Health Sciences Türkiye, Dr. Suat Seren Chest Diseases and Thoracic Surgery Training and Research Hospital, İzmir, Türkiye",
        "orcid": ""
      },
      {
        "name": "Süleyman Yıldırım",
        "affiliation": "Department of Critical Care Medicine, University of Health Sciences Türkiye, Dr. Suat Seren Chest Diseases and Thoracic Surgery Training and Research Hospital, İzmir, Türkiye",
        "orcid": ""
      },
      {
        "name": "Kübra Saçar Kübüç",
        "affiliation": "Clinic of Critical Care Medicine, University of Health Sciences Türkiye, Van Training and Research Hospital, Van, Türkiye",
        "orcid": ""
      },
      {
        "name": "Ayşen Erer",
        "affiliation": "Clinic of Critical Care Medicine, Tekirdağ İsmail Fehmi Cumalioğlu City Hospital, Tekirdag, Türkiye",
        "orcid": ""
      },
      {
        "name": "Hamza Gültekin",
        "affiliation": "Clinic of Critical Care Medicine, Şırnak State Hospital, Şırnak, Türkiye",
        "orcid": ""
      },
      {
        "name": "Kezban Özmen Süner",
        "affiliation": "Clinic of Critical Care Medicine, Sakarya Training and Research Hospital, Sakarya, Türkiye",
        "orcid": ""
      },
      {
        "name": "Özge Kuzgun",
        "affiliation": "Clinic of Critical Care Medicine, Sakarya Training and Research Hospital, Sakarya, Türkiye",
        "orcid": ""
      },
      {
        "name": "Çağatay Erman Öztürk",
        "affiliation": "Clinic of Critical Care Medicine, University of Health Sciences Türkiye, Samsun Training and Research Hospital, Samsun, Türkiye",
        "orcid": ""
      },
      {
        "name": "Aydın Karahan",
        "affiliation": "Clinic of Critical Care Medicine, Mersin City Hospital, Mersin, Türkiye",
        "orcid": ""
      },
      {
        "name": "Okan Deveci",
        "affiliation": "Clinic of Critical Care Medicine, Mersin City Hospital, Mersin, Türkiye",
        "orcid": ""
      },
      {
        "name": "Mustafa Ay",
        "affiliation": "Clinic of Anesthesiology and Reanimation, Antalya Training and Research Hospital, Antalya, Türkiye",
        "orcid": ""
      },
      {
        "name": "Dilara Tüfek Öztan",
        "affiliation": "Clinic of Anesthesiology and Reanimation, Antalya Training and Research Hospital, Antalya, Türkiye",
        "orcid": ""
      },
      {
        "name": "Seda Banu Akıncı",
        "affiliation": "Division of Critical Care Medicine, Department of Anesthesiology and Reanimation, Hacettepe University Faculty of Medicine, Ankara, Türkiye",
        "orcid": ""
      },
      {
        "name": "et al </d",
        "affiliation": "",
        "orcid": ""
      }
    ],
    "abstract": "Abstract Background: Vaccines against coronavirus disease-19 (COVID-19) have been effective in preventing symptomatic diseases, hospitalizations, and intensive care unit (ICU) admissions. However, data regarding the effectiveness of COVID-19 vaccines in reducing mortality among critically ill patients with COVID-19 remains unclear.Aims: To determine the vaccination status and investigate the impact of the COVID-19 vaccine on the 28-day mortality in critically ill patients with COVID-19.Study Design: Multicenter prospective observational clinical study.Methods: This study was conducted in 60 hospitals with ICUs managing critically ill patients with COVID-19. Patients aged ≥ 18 years with confirmed COVID-19 who were admitted to the ICU were included. The present study had two phases. The first phase was designed as a one-day point prevalence study, and demographic and clinical findings were evaluated. In the second phase, the 28-day mortality was evaluated.Results: As of August 11, 2021, 921 patients were enrolled in the study. The mean age of the patients was 65.42 ± 16.74 years, and 48.6% (n = 448) were female. Among the critically ill patients with COVID-19, 52.6% (n = 484) were unvaccinated, 7.7% (n = 71) were incompletely vaccinated, and 39.8% (n = 366) were fully vaccinated. A subgroup analysis of 817 patients who were unvaccinated (n = 484) or who had received two doses of the CoronaVac vaccine (n = 333) was performed. The 28-day mortality rate was 56.8% (n = 275) and 57.4% (n = 191) in the unvaccinated and two-dose CoronaVac groups, respectively. The 28-day mortality was associated with age, hypertension, the number of comorbidities, type of respiratory support, and APACHE II and sequential organ failure assessment scores (p < 0.05). The odds ratio for the 28-day mortality among those who had received two doses of CoronaVac was 0.591 (95% confidence interval: 0.413-0.848) (p = 0.004).Conclusion: Vaccination with at least two doses of CoronaVac within six months significantly decreased mortality in vaccinated patients than in unvaccinated patients.",
    "abstractHtml": "<div class=\"col-lg-12 col-md-12 col-sm-12 col-xs-12\">\n\t\t\t<h4>Abstract</h4>\r\n<p><strong>Background:</strong> Vaccines against coronavirus disease-19 (COVID-19) have been effective in preventing symptomatic diseases, hospitalizations, and intensive care unit (ICU) admissions. However, data regarding the effectiveness of COVID-19 vaccines in reducing mortality among critically ill patients with COVID-19 remains unclear.<br /><strong>Aims:</strong> To determine the vaccination status and investigate the impact of the COVID-19 vaccine on the 28-day mortality in critically ill patients with COVID-19.<br /><strong>Study Design:</strong> Multicenter prospective observational clinical study.<br /><strong>Methods:</strong> This study was conducted in 60 hospitals with ICUs managing critically ill patients with COVID-19.&nbsp; Patients aged &ge; 18 years with confirmed COVID-19 who were admitted to the ICU were included. The present study had two phases. The first phase was designed as a one-day point prevalence study, and demographic and clinical findings were evaluated. In the second phase, the 28-day mortality was evaluated.<br /><strong>Results:</strong> As of August 11, 2021, 921 patients were enrolled in the study. The mean age of the patients was 65.42 &plusmn; 16.74 years, and 48.6% (n = 448) were female. Among the critically ill patients with COVID-19, 52.6% (n = 484) were unvaccinated, 7.7% (n = 71) were incompletely vaccinated, and 39.8% (n = 366) were fully vaccinated. A subgroup analysis of 817 patients who were unvaccinated (n = 484) or who had received two doses of the CoronaVac vaccine (n = 333) was performed. The 28-day mortality rate was 56.8% (n = 275) and 57.4% (n = 191) in the unvaccinated and two-dose CoronaVac groups, respectively. The 28-day mortality was associated with age, hypertension, the number of comorbidities, type of respiratory support, and APACHE II and sequential organ failure assessment scores (<em>p</em> &lt; 0.05). The odds ratio for the 28-day mortality among those who had received two doses of CoronaVac was 0.591 (95% confidence interval: 0.413-0.848) (<em>p</em> = 0.004).<br /><strong>Conclusion:</strong> Vaccination with at least two doses of CoronaVac within six months significantly decreased mortality in vaccinated patients than in unvaccinated patients.</p> \t\t\t\t\t\t        \t\t\t\t\t\n\t\t\t</div>",
    "previewText": "Abstract Background: Vaccines against coronavirus disease-19 (COVID-19) have been effective in preventing symptomatic diseases, hospitalizations, and intensive care unit (ICU) admissions. However, data regarding the effectiveness of COVID-19 vaccines in reducing mortality among critically ill patients with COVID-19 remains unclear.Aims: To determine the vaccination status and investigate the impact of the COVID-19 vaccine on the 28-day mortality in critically ill patients with COVID-19.Study Design: Multicenter prospective observational clinical study.Methods: This study was conducted in 60 hospitals with ICUs managing critically ill patients with COVID-19. Patients aged ≥ 18 years with confirmed COVID-19 who were admitted to the ICU were included. The present study had two phases. The first phase was designed as a one-day point prevalence study, and demographic and clinical findings were evaluated. In the second phase, the 28-day mortality was evaluated.Results: As of August 11, 2021, 921 patients were enrolled in the study. The mean age of the patients was 65.42 ± 16.74 years, and 48.6% (n = 448) were female. Among the critically ill patients with COVID-19, 52.6% (n = 484) were unvaccinated, 7.7% (n = 71) were incompletely vaccinated, and 39.8% (n = 366) were fully vaccinated. A subgroup analysis of 817 patients who were unvaccinated (n = 484) or who had received two doses of the CoronaVac vaccine (n = 333) was performed. The 28-day mortality rate was 56.8% (n = 275) and 57.4% (n = 191) in the unvaccinated and two-dose CoronaVac groups, respectively. The 28-day mortality was associated with age, hypertension, the number of comorbidities, type of respiratory support, and APACHE II and sequential organ failure assessment scores (p < 0.05). The odds ratio for the 28-day mortality among those who had received two doses of CoronaVac was 0.591 (95% confidence interval: 0.413-0.848) (p = 0.004).Conclusion: Vaccination with at least two doses of CoronaVac within six months significantly decreased mortality in vaccinated patients than in unvaccinated patients.",
    "keywords": [],
    "doi": "10.4274/balkanmedj.galenos.2023.2023-6-90",
    "received": "",
    "accepted": "",
    "published": "2023-01-01",
    "volume": 40,
    "issue": "6",
    "pages": "435-444",
    "views": 6676,
    "downloads": 4740,
    "citations": 0,
    "featured": false,
    "imageCorner": false,
    "hasFullText": true,
    "sourceIssueId": "1287",
    "sourceArticleId": "2546",
    "sourceAbstractUrl": "https://balkanmedicaljournal.org/abstract.php?id=2546",
    "sourceTextUrl": "https://balkanmedicaljournal.org/text.php?lang=en&id=2546",
    "sourcePdfUrl": "https://balkanmedicaljournal.org/pdf.php?&id=2546",
    "localPdfUrl": "js/data/pdfs/2546.pdf",
    "pdfUrl": "js/data/pdfs/2546.pdf"
  },
  {
    "id": 2537,
    "type": "Clinical Image",
    "title": "Marchiafava-Bignami Disease in a Patient with Anorexia Nervosa",
    "authors": [
      {
        "name": "Hiroaki Nishioka",
        "affiliation": "Department of General Internal Medicine, Kobe City Medical Center General Hospital, Hyogo, Japan",
        "orcid": ""
      },
      {
        "name": "Hiroki Kamei",
        "affiliation": "Department of General Internal Medicine, Kobe City Medical Center General Hospital, Hyogo, Japan",
        "orcid": ""
      }
    ],
    "abstract": "",
    "abstractHtml": "",
    "previewText": "A 15-year-old girl was transferred to our emergency room with a three-day history of altered mental status and impaired speech function. She also had appetite loss for seven days and received a drip containing thiamine 20 mg at the previous clinic. She had been diagnosed with anorexia nervosa (AN) two years ago, repeated anorexia, and overeating. She had no ",
    "keywords": [],
    "doi": "10.4274/balkanmedj.galenos.2023.2023-7-68",
    "received": "",
    "accepted": "",
    "published": "2023-01-01",
    "volume": 40,
    "issue": "6",
    "pages": "445-446",
    "views": 5441,
    "downloads": 3220,
    "citations": 0,
    "featured": false,
    "imageCorner": true,
    "hasFullText": true,
    "sourceIssueId": "1287",
    "sourceArticleId": "2537",
    "sourceAbstractUrl": "https://balkanmedicaljournal.org/abstract.php?id=2537",
    "sourceTextUrl": "https://balkanmedicaljournal.org/text.php?lang=en&id=2537",
    "sourcePdfUrl": "https://balkanmedicaljournal.org/pdf.php?&id=2537",
    "localPdfUrl": "js/data/pdfs/2537.pdf",
    "pdfUrl": "js/data/pdfs/2537.pdf"
  },
  {
    "id": 2547,
    "type": "Clinical Image",
    "title": "Diffuse Idiopathic Colonic Varices: Demonstration Using Multiplanar Reconstructions from Triphasic Computed Tomography",
    "authors": [
      {
        "name": "Mustafa Kemal Demir",
        "affiliation": "Clinic of Radiology, Bahçeşehir University Göztepe Medical Park Hospital, İstanbul, Türkiye",
        "orcid": ""
      },
      {
        "name": "Özge Ecertaştan",
        "affiliation": "Intern Medical Student, Bahçeşehir University Faculty of Medicine, İstanbul, Türkiye",
        "orcid": ""
      }
    ],
    "abstract": "",
    "abstractHtml": "",
    "previewText": "A 37-year-old male presented to the emergency department following an episode of melena. He had no abdominal pain or any significant weight or appetite loss. No changes were observed in his bowel habits. He was healthy and did not taken any regular medication. His family history and general physical examination findings were unremarkable. Laboratory examinat",
    "keywords": [],
    "doi": "10.4274/balkanmedj.galenos.2023.2023-8-99",
    "received": "",
    "accepted": "",
    "published": "2023-01-01",
    "volume": 40,
    "issue": "6",
    "pages": "447-448",
    "views": 4877,
    "downloads": 2885,
    "citations": 0,
    "featured": false,
    "imageCorner": true,
    "hasFullText": true,
    "sourceIssueId": "1287",
    "sourceArticleId": "2547",
    "sourceAbstractUrl": "https://balkanmedicaljournal.org/abstract.php?id=2547",
    "sourceTextUrl": "https://balkanmedicaljournal.org/text.php?lang=en&id=2547",
    "sourcePdfUrl": "https://balkanmedicaljournal.org/pdf.php?&id=2547",
    "localPdfUrl": "js/data/pdfs/2547.pdf",
    "pdfUrl": "js/data/pdfs/2547.pdf"
  },
  {
    "id": 2536,
    "type": "Clinical Image",
    "title": "Double Coronary-Cameral Fistula Draining to the Right Ventricle in a Patient with Mitral Stenosis: is it Clinically Relevant?",
    "authors": [
      {
        "name": "Mustafa Ebik",
        "affiliation": "Clinic of Cardiology, Edirne Sultan 1. Murat State Hospital, Edirne, Türkiye",
        "orcid": ""
      },
      {
        "name": "Cihan Öztürk",
        "affiliation": "Department of Cardiology, Trakya University Faculty of Medicine, Edirne, Türkiye",
        "orcid": ""
      },
      {
        "name": "Fethi Emre Ustabaşıoğlu",
        "affiliation": "Department of Radiology, Trakya University Faculty of Medicine, Edirne, Türkiye",
        "orcid": ""
      }
    ],
    "abstract": "",
    "abstractHtml": "",
    "previewText": "A 39-year-old female patient was admitted to the cardiology outpatient clinic with complaints of dyspnea on exertion and fatigue that had been present for the last 3-4 months. History assessment revealed that the patient had an episode of acute rheumatic fever at the age of 10 years, but was lost to follow-up since then. Within the last 6 months, she had bee",
    "keywords": [],
    "doi": "10.4274/balkanmedj.galenos.2023.2023-7-28",
    "received": "",
    "accepted": "",
    "published": "2023-01-01",
    "volume": 40,
    "issue": "6",
    "pages": "449-450",
    "views": 4938,
    "downloads": 2729,
    "citations": 0,
    "featured": false,
    "imageCorner": true,
    "hasFullText": true,
    "sourceIssueId": "1287",
    "sourceArticleId": "2536",
    "sourceAbstractUrl": "https://balkanmedicaljournal.org/abstract.php?id=2536",
    "sourceTextUrl": "https://balkanmedicaljournal.org/text.php?lang=en&id=2536",
    "sourcePdfUrl": "https://balkanmedicaljournal.org/pdf.php?&id=2536",
    "localPdfUrl": "js/data/pdfs/2536.pdf",
    "pdfUrl": "js/data/pdfs/2536.pdf"
  },
  {
    "id": 2528,
    "type": "Scientific Letter",
    "title": "Testicular Pain is the First Symptom of Lung Squamous Cell Carcinoma Metastasizing to the Testis",
    "authors": [
      {
        "name": "Chendong He",
        "affiliation": "Department of Radiology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China",
        "orcid": ""
      },
      {
        "name": "Wei Yang",
        "affiliation": "Department of Radiology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu, China",
        "orcid": ""
      },
      {
        "name": "Fenglin Ge",
        "affiliation": "Department of Pathology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu, China",
        "orcid": ""
      }
    ],
    "abstract": "",
    "abstractHtml": "",
    "previewText": "A 67-year-old male presented with a two-month history of left-sided testicular pain of unknown etiology. Color Doppler ultrasonography revealed a hypoechoic area in the left testis, measuring approximately 3.1 x 2.2 cm, with ill-defined borders and heterogeneous internal echogenicity; blood flow signals were also observed within the lesion (Figure 1a). The s",
    "keywords": [],
    "doi": "10.4274/balkanmedj.galenos.2023.2022-6-86",
    "received": "",
    "accepted": "",
    "published": "2023-01-01",
    "volume": 40,
    "issue": "6",
    "pages": "451-453",
    "views": 5272,
    "downloads": 3395,
    "citations": 0,
    "featured": false,
    "imageCorner": false,
    "hasFullText": true,
    "sourceIssueId": "1287",
    "sourceArticleId": "2528",
    "sourceAbstractUrl": "https://balkanmedicaljournal.org/abstract.php?id=2528",
    "sourceTextUrl": "https://balkanmedicaljournal.org/text.php?lang=en&id=2528",
    "sourcePdfUrl": "https://balkanmedicaljournal.org/pdf.php?&id=2528",
    "localPdfUrl": "js/data/pdfs/2528.pdf",
    "pdfUrl": "js/data/pdfs/2528.pdf"
  },
  {
    "id": 2525,
    "type": "Scientific Letter",
    "title": "Premature Ejaculation-Emerging Concepts and a Novel Classification",
    "authors": [
      {
        "name": "Arkiath Veettil Raveendran",
        "affiliation": "Department of Internal Medicine, Badr Al Samaa Hospital, Muscat, Oman",
        "orcid": ""
      }
    ],
    "abstract": "",
    "abstractHtml": "",
    "previewText": "Premature ejaculation (PE) or early ejaculation is a common male sexual dysfunction.1 Various professional bodies have provided different definitions for PE. The International Society of Sexual Medicine, 2014, defines PE as follows: “Ejaculation that always or nearly always occurs prior to or within about 1 minute of vaginal penetration from the first sexual",
    "keywords": [],
    "doi": "10.4274/balkanmedj.galenos.2023.2023-6-47",
    "received": "",
    "accepted": "",
    "published": "2023-01-01",
    "volume": 40,
    "issue": "6",
    "pages": "454-455",
    "views": 10881,
    "downloads": 4207,
    "citations": 0,
    "featured": false,
    "imageCorner": false,
    "hasFullText": true,
    "sourceIssueId": "1287",
    "sourceArticleId": "2525",
    "sourceAbstractUrl": "https://balkanmedicaljournal.org/abstract.php?id=2525",
    "sourceTextUrl": "https://balkanmedicaljournal.org/text.php?lang=en&id=2525",
    "sourcePdfUrl": "https://balkanmedicaljournal.org/pdf.php?&id=2525",
    "localPdfUrl": "js/data/pdfs/2525.pdf",
    "pdfUrl": "js/data/pdfs/2525.pdf"
  },
  {
    "id": 2544,
    "type": "Scientific Letter",
    "title": "Cutaneous Involvement as a First Sign of CD5(-) Blastoid Mantle Cell Lymphoma",
    "authors": [
      {
        "name": "Emre Zekey",
        "affiliation": "Clinic of Dermatology, Sivas State Hospital, Sivas, Türkiye",
        "orcid": ""
      },
      {
        "name": "Şule Öztürk Sarı",
        "affiliation": "Department of Pathology, İstanbul University İstanbul Medical Faculty,İstanbul, Türkiye",
        "orcid": ""
      },
      {
        "name": "Gülçin Yeğen",
        "affiliation": "Department of Pathology, İstanbul University İstanbul Medical Faculty,İstanbul, Türkiye",
        "orcid": ""
      },
      {
        "name": "Seher Darakcı",
        "affiliation": "Clinic of Pathology, Sivas State Hospital, Sivas, Türkiye",
        "orcid": ""
      }
    ],
    "abstract": "",
    "abstractHtml": "",
    "previewText": "Mantle cell lymphoma (MCL) is a subtype of B-cell non-Hodgkin’s lymphoma and is cytomorphologically divided into several subtypes: blastoid, pleomorphic, small-cell, and marginal zone-like.1 The blastoid variant has an aggressive course, and skin involvement is seen in about 2% of cases. Skin involvement is associated with poorer prognosis and extremely rare",
    "keywords": [],
    "doi": "10.4274/balkanmedj.galenos.2023.2023-7-96",
    "received": "",
    "accepted": "",
    "published": "2023-01-01",
    "volume": 40,
    "issue": "6",
    "pages": "456-459",
    "views": 5500,
    "downloads": 3220,
    "citations": 0,
    "featured": false,
    "imageCorner": false,
    "hasFullText": true,
    "sourceIssueId": "1287",
    "sourceArticleId": "2544",
    "sourceAbstractUrl": "https://balkanmedicaljournal.org/abstract.php?id=2544",
    "sourceTextUrl": "https://balkanmedicaljournal.org/text.php?lang=en&id=2544",
    "sourcePdfUrl": "https://balkanmedicaljournal.org/pdf.php?&id=2544",
    "localPdfUrl": "js/data/pdfs/2544.pdf",
    "pdfUrl": "js/data/pdfs/2544.pdf"
  },
  {
    "id": 2548,
    "type": "Reviewer List",
    "title": "REVIEWER LIST",
    "authors": [],
    "abstract": "",
    "abstractHtml": "",
    "previewText": "40rd Volume IndexREVIEWER LISTJanuary 2023 - November 2023 Abdi Özaslan George P. Patrinos Olivier Sitbon Abdil Cem İbiş Gerda Elisabeth Villadsen Onur Kirkizlar Adem Atıcı Gianluca Pellino Orhan Uzun Aditya K. Panda Giovanni Targher Osman Köstek Adriano Casulli Guang-Yao Lin Osman Şimşek Ágnes Sonnevend Guangdong Yang Oya Demirci Ahmet Gül Guido Kroemer Ozg",
    "keywords": [],
    "doi": "",
    "received": "",
    "accepted": "",
    "published": "2023-01-01",
    "volume": 40,
    "issue": "6",
    "pages": "",
    "views": 4983,
    "downloads": 1815,
    "citations": 0,
    "featured": false,
    "imageCorner": false,
    "hasFullText": true,
    "sourceIssueId": "1287",
    "sourceArticleId": "2548",
    "sourceAbstractUrl": "https://balkanmedicaljournal.org/abstract.php?id=2548",
    "sourceTextUrl": "https://balkanmedicaljournal.org/text.php?lang=en&id=2548",
    "sourcePdfUrl": "https://balkanmedicaljournal.org/pdf.php?&id=2548",
    "localPdfUrl": "js/data/pdfs/2548.pdf",
    "pdfUrl": "js/data/pdfs/2548.pdf"
  }
]